The Journal of the Korea Contents Association (한국콘텐츠학회논문지)

The Korea Contents Association (한국콘텐츠학회)
권호 표지
DOI QR코드

DOI QR Code

Occurrence and Prognosis for the Thrombosis in the Drug-Eluting Stents and Bare-Metal Stents

약물 용출 스텐트와 일반 금속 스텐트에서 혈전증에 대한 발생과 예후

  • 김인수 (동신대학교 방사선학과) ;
  • 최남길 (동신대학교 방사선학과) ;
  • 장성주 (동신대학교 방사선학과) ;
  • 한재복 (동신대학교 방사선학과) ;
  • 장영일 (광양보건대학교 방사선과)
  • Received : 2012.04.27
  • Accepted : 2012.05.31
  • Published : 2012.07.28
Download PDF
⟨ Previous Next ⟩

Abstract

Drug-eluting stents (DES) have significantly reduced in-stent restenosis, compared to bare-metal stents (BMS). However, there remains concern for the increased risk of stent thrombosis (ST) associated with DES. The present study sought to evaluate the incidence, clinical characteristics and outcome of ST in patients with acute myocardial infarction (MI) during a 1-year follow-up. 80 patients who developed ST were divided into 2 groups according to stent type: group I (DES-ST, n = 57 ) and group II (BMS-ST, n = 23 ). There were no differences between group I and II in the overall incidence of ST (2.7% vs. 4.3%, p=0.064) and in the incidence of each type of ST: acute ST (8.8% vs. 2.3%), subacute ST (50.9% vs. 60.9%), late ST (19.3% vs. 8.7%), and very late ST (21.1% vs. 17.4%) (p=0.605). Predictors of 1-year mortality were the occurrence of ST (OR 8.12, 95% CI 2.83-23.61, p<0.001), left ventricular ejection fraction<40% (OR 6.41, 95% CI 2.42-16.96, p<0.001), and age${\geq}$75 years (OR 4.98, 95% CI 1.95-12.74, p=0.001).

급성심근경색증 환자에서 약물 용출 스텐트(drug-eluting stents, DES)는 일반 금속 스텐트(bare-metal stents, BMS)에 비해 재협착은 감소하지만 구조적인 특성으로 스텐트 혈전증(stent thrombosis, ST)이 증가한다고 알려져 있다. 이에 본 연구에서는 ST의 발생빈도, 임상양상, 그리고 1년간 예후를 알아보고자 하였다. 대학병원 심혈관센터에서 급성심근경색증으로 관상동맥 중재술을 받은 2,667명에서 스텐트 혈전증이 발생한 환자 80명을 대상으로 DES-ST를 I군(n=57), BMS-ST(n=23)를 II군으로 분류하여 양군 간의 특징을 분석하였다. 양군간의 ST는 I군에서 57명(2.7%)과 II군에서 23명(4.3%)로 양군 간에 유의한 차이는 없었다(p>0.064). ST의 유형으로는 acute ST는 I군5(8.8%), II군3(2.3%), subacute ST는 I군 29(50.9%), II군14(60.9%), late ST 는 I군11(19.3%), II군2(8.7%), very late ST는 I군12(21.1%), II군 4(17.4%)로 양군간의 차이는 없었다(p>0.605). DES와 BMS를 삽입 후 1년 예후에 미치는 인자로는 ST(OR 8.166 95% CI 2.825-23.608 p<0.001), 좌심실구혈율(<40) (OR 6.409 95% CI 2.422-16.955 p<0.001), 나이(${\geq}$75세) (OR 4.979 95% CI 1.946-12.744 p=0.001) 이었다. ST의 발생율은 양군 사이에 차이가 없었고, 1년 예후에 미치는 인자로는 ST의 발생, 좌심실 구혈률의 저하 및 환자의 연령 등 이었다.

Keywords

References

  1. J. E. Sousa, M. A. Costa, and A. Abizaid, "Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study," Circulation, Vol.103, pp.192-195, 2001. https://doi.org/10.1161/01.CIR.103.2.192
  2. J. W. Moses, M. B. Leon, and J. J. Popma, "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery," N Engl J Med, Vol.349, pp.1315-1323, 2003. https://doi.org/10.1056/NEJMoa035071
  3. J. E. Sousa, M. A. Costa, and A. G. Sousa, "Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries," Circulation, Vol.107, pp.381-383, 2003. https://doi.org/10.1161/01.CIR.0000051720.59095.6D
  4. G. W. Stone, S. G. Ellis, and D. A. Cox, "One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent," Circulation, Vol.109, pp.1942-1947, 2004. https://doi.org/10.1161/01.CIR.0000127110.49192.72
  5. M. C. Morice, P. W. Serruys, and J. E. Sousa, "A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization," N Engl J Med, Vol.346, pp.1773-1780, 2002. https://doi.org/10.1056/NEJMoa012843
  6. J. W. Moses, M. B. Leon, and J. J. Popma, "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery," N Engl J Med, Vol.349, pp.1315-1323, 2003. https://doi.org/10.1056/NEJMoa035071
  7. G. W. Stone, S. G. Ellis, and D. A. Cox, "A polymer-based, paclitaxelelutin stent in patients with coronary artery disease," N Engl J Med, Vol.350, pp.221-231, 2004. https://doi.org/10.1056/NEJMoa032441
  8. A. Colombo, J. Drzewiecki, and A. Banning, "Randomized study to assess the effectiveness of slow- and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions," Circulation, Vol.108, pp.788-794, 2003. https://doi.org/10.1161/01.CIR.0000086926.62288.A6
  9. E. Schampaert, E. A. Cohen, and M. Schluter, "The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)," J Am Coll Cardiol, Vol.43, pp.1110-1115, 2004. https://doi.org/10.1016/j.jacc.2004.01.024
  10. J. Schofer, M. Schluter, and A. H. Gershlick, "Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)," Lancet, Vol.362, pp.1093-1099, 2003. https://doi.org/10.1016/S0140-6736(03)14462-5
  11. S. J. Park, Y. H. Kim, and B. K. Lee, "Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation," J Am Coll Cardiol, Vol.45, pp.351-356, 2005. https://doi.org/10.1016/j.jacc.2004.10.039
  12. I. S. Kim, J. B. Han, S. J. Jang, and Y. I. Jang, "The Study on the Independent Predictive Factor of Restenosis afterPercutaneous Coronary Intervention used Drug-Eluting Stent : Case on MDCT Calcium-Scoring Implementation Patient," 방사선기술학회지, Vol.33, No.1, pp.37-44, 2010.
  13. A. Jeremias, B. Sylvia, and J. Bridges, "Stent thrombosis after successful sirolimus-eluting stent implantation," Circulation, Vol.109, pp.1930-1932, 2004. https://doi.org/10.1161/01.CIR.0000127105.99982.21
  14. D. W. Park and S. W. Park, "Stent thrombosis in the era of the drugeluting stent," Korean Circ J, Vol.35, pp.791-794, 2005. https://doi.org/10.4070/kcj.2005.35.11.791
  15. S. Park, G. R. Hong, H. S. Seo, and S. J. Tahk, "Stent thrombosis after successful drug-eluting stent implantation," Korean Circ J, Vol.35, pp.163-171, 2005. https://doi.org/10.4070/kcj.2005.35.2.163
  16. J. Daemen, H. M. Garcia-Garcia, and N. Kukreja, "The long-term value of sirolimusand paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus," Eur Heart J, Vol.28, pp.26-32, 2007.
  17. S. G. Ellis, A. Colombo, and E. Grube, "Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years," J Am Coll Cardiol, Vol.49, pp.1043-1051, 2007. https://doi.org/10.1016/j.jacc.2007.01.015
  18. R. Moreno, C. Fernandez, and R. Hernandez, "Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies," J Am Coll Cardiol, Vol.45, pp.954-959, 2005. https://doi.org/10.1016/j.jacc.2004.11.065
  19. E. Schampaert, J. W. Moses, and J. Schofer "Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses," Am J Cardiol, Vol.98, pp.36-41, 2006. https://doi.org/10.1016/j.amjcard.2006.01.049
  20. D. E. Cutlip, S. Windecker, and R. Mehran, "Clinical end points in coronary stent trials: a case for standardized definitions," Circulation, Vol.115, No.17, pp.2344-2345, 2007. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
  21. J. H. Moon, M. H. Jeong, and I. S. Kim, "The Frequency, Treatment and Clinical Outcomes of Stent Thrombosi after Use of TAXUSTM Stent," Korean Circ J, Vol.37, pp.641-646, 2007. https://doi.org/10.4070/kcj.2007.37.12.641
  22. A. Farb and A. B. Boam, "Stent thrombosis redux: the FDA perspective," N Engl J Med, Vol.356, pp.984-987, 2007. https://doi.org/10.1056/NEJMp068304
  23. G. De Luca, G. Carbone, A. Maione, and G. Gregorio, "In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report," Int J Cardiol, Vol.116, pp.399-400, 2007. https://doi.org/10.1016/j.ijcard.2006.02.033
  24. R. Artang and R. S. Dieter, "Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries," Am J Cardiol, Vol.99, pp.1039-1043, 2007. https://doi.org/10.1016/j.amjcard.2006.12.025
  25. C. L. Grines, R. O. Bonow, and D. E. Jr Casey, "Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians," Catheter Cardiovasc Interv, Vol.69, pp.334-340, 2007. https://doi.org/10.1002/ccd.21124
  26. F. Burzotta, E. Romagnoli, and A. Manzoli, "The Outcome of PCI for stent-ThrombosIs MultIcentre Study (OPTIMIST): rationale and design of a multicenter registry," Am Heart J Vol.153, p.377, 2007.
  27. US Food and Drug Administration Public Health Web Notification, "FDA advises physicians of adverse events associated with Cordis Cypher coronary stents," T03-T71, 2003.
  28. I. Iakovou, T. Schmidt, and E. Bonizzoni, "Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents," JAMA, Vol.293, pp.2126-2130, 2005. https://doi.org/10.1001/jama.293.17.2126
  29. J. Daemen, P. Wenaweser, and K. Tsuchida, "Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study," Lancet, Vol.369, pp.667-678, 2007. https://doi.org/10.1016/S0140-6736(07)60314-6
  30. J. Oyabu, Y. Ueda, N. Ogasawara, K. Okada, A. Hirayama, and K. Kodama, "Angioscopic evaluation of neointima coverage: sirolimus drugeluting stent versus bare metal stent," Am Heart J, Vol.152, pp.1168-1174, 2006. https://doi.org/10.1016/j.ahj.2006.07.025
  31. H. W. Park, M. H. Jeong, and O. Y. Park, "The long-term clinical effects of heparin coated coronary stent," Korean Circ J, Vol.32, pp.773-780, 2002. https://doi.org/10.4070/kcj.2002.32.9.773
  32. W. Kim, M. H. Jeong, and K.S. Cha, "The effect of anti-oxidants (carvedilol and probucol) loaded stents in a porcine coronary restenosis model," Circ J, Vol.69, pp.101-106, 2005. https://doi.org/10.1253/circj.69.101
  33. W. Kim, M. H. Jeong, and Y. J. Hong, "The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab:$ReoPro^{(R)}$) coated stent in patients with acute myocardial infarction," Korean Circ J, Vol.34, pp.1063-1069, 2004. https://doi.org/10.4070/kcj.2004.34.11.1063
  34. Y. J. Hong, M. H. Jeong, and W. Kim "Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries," Am J Cardiol, Vol.94, pp.1050-1054, 2004. https://doi.org/10.1016/j.amjcard.2004.06.066
  35. O. Y. Park, M. H. Jeong, and J. H. Kim, "The inhibitory effects of a platelet glycoprotein IIb/IIIa receptor blocker-coated stent on neointima formation and inflammatory response in porcine coronary stent restenosis," Korean Circ J, Vol.33, pp.439-445, 2003. https://doi.org/10.4070/kcj.2003.33.5.439
  36. S. Y. Lim and M. H. Jeong, "Is heparin-coated stent effective in patients with acute myocardial infarction?," Korean Circ J, Vol.34, pp.537-539, 2004. https://doi.org/10.4070/kcj.2004.34.6.537
  37. W. Kim, M. H. Jeong, and K. H. Kim, "The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab-ReoPro) -coated stent in acute myocardial infarction," J Am Coll Cardiol, Vol.47, pp.933-938, 2006. https://doi.org/10.1016/j.jacc.2005.10.054
  38. S. Y. Lim, E. H. Bae, and M. H. Jeong "The effect of oral administration of alpha lipoic acid and alpha lipoic acid coated stent in porcine in-stent restenosis model," Korean Circ J, Vol.36, pp.495-502, 2006. https://doi.org/10.4070/kcj.2006.36.7.495
  39. P. W. Serruys, B. H. Strauss, H. M. van Beusekom, and W. J. van der Giessen, "Stenting of coronary arteries: has a modern Pandora' box been opened?," J Am Coll Cardiol, Vol.17, pp.143B-154B, 1991.